Last reviewed · How we verify
Extended sequential therapy
Extended sequential therapy is a treatment regimen that combines multiple therapeutic agents administered in a planned sequence to optimize clinical outcomes.
At a glance
| Generic name | Extended sequential therapy |
|---|---|
| Also known as | S-14 |
| Sponsor | Fu Jen Catholic University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This approach involves the sequential administration of different therapeutic modalities (such as chemotherapy, immunotherapy, or targeted agents) in a coordinated schedule rather than concurrently. The sequential design aims to maximize efficacy by allowing each treatment phase to exert its effect before transitioning to the next, potentially reducing toxicity and improving tolerability while maintaining or enhancing therapeutic benefit.
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (PHASE2)
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer (NA)
- A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) (PHASE2, PHASE3)
- A Study of Idazoxan in Healthy Participants (PHASE1)
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (PHASE3)
- A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) (PHASE2)
- Effects of Combined Upper Extremity Exercise and Pneumatic Compression Therapy on Breast Cancer-Related Lymphedema (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended sequential therapy CI brief — competitive landscape report
- Extended sequential therapy updates RSS · CI watch RSS
- Fu Jen Catholic University Hospital portfolio CI